We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Ximbio Reagent Trading Portal Increases Portfolio by Over 40% in First Year

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Ximbio Reagent Trading Portal Increases Portfolio by Over 40% in First Year"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ximbio has increased the number of reagents in its portfolio by 42% since the website launched in October last year. The company now has more than 20 research institutes from the UK, Europe and the USA enlisted to virtually deposit their reagents.

Ximbio provides a portal for the life science community to exchange knowledge and trade reagents. Researchers and technology transfer offices can virtually upload their reagents to the Ximbio website. Bench scientists can make informed decisions about which reagents to use, though the Ximbio searchable database, extensive datasheets, peer reviews and supplier options. Each reagent record can be linked to the originating inventor, enabling scientists and institutions to raise the profile of their work.

All reagents listed on Ximbio are supported with originating data on the generation and validation of the tool. There are now over 2,500 peer-reviewed references, linked to 1,401 reagents, which are accessible to every user.

“In recent months, we have seen an increased awareness across the research community for the need for data reproducibility. Scientists are becoming more critical of the antibodies and other reagents they are using, and access to characterization data is something that more researchers are asking for. At Ximbio we are committed to both antibody reproducibility, and open source information, which is why we ensure all new reagents listed on the website have supporting data or a peer reviewed journal showing how the tool was created or validated.” commented Melanie Hardman, Head of Ximbio.

Life science companies can use Ximbio to easily source new products to augment their portfolios via a straightforward commercialization process. The company has a global reach, with over 200 suppliers and biotech companies licensing products through Ximbio, from the US, Europe, Asia and Australia.